Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / HSP90a



This biomarker is also known as:
  • HSPC1,
  • Hsp89,
  • Hsp90,
  • HSP89A,
  • FLJ31884,
  • HSP90AA1,
  • heat shock protein 90kDa alpha (cytosolic), class A member 1,
  • LAP2,
  • heat shock 90kD protein 1, alpha,
  • Heat shock 86 kDa,
  • heat shock 90kD protein, alpha-like 4,
  • heat shock 86 kDa,
  • heat shock 90kD protein 1, alpha-like 4,
  • HSPCAL4,
  • heat shock 90kDa protein 1, alpha,
  • HSPN,
  • HSP86,
  • HSP90N,
  • HSPCA,
  • renal carcinoma antigen NY-REN-38,
  • HSPCAL1,
  • HSP90A,
  • heat shock protein HSP 90-alpha,
  • Renal carcinoma antigen NY-REN-38,
  • HSP 86,

View in BioMuta


The HSP90AA1 protein, also known as HSP90a, is a molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved in cell cycle control and signal transduction. HSP90AA1 is a homodimer that assists in the proper folding of specific target proteins by use of an ATPase activity that is modulated by co-chaperones. Two transcript variants encoding different isoforms have been found for this gene.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


HSP90a is important for the stability of and function of a wide range of oncoproteins and has been been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker.

Performance Comment

It has been shown that levels of HSP90a were elevated in lung cancer patients, and that the levels of HSP90a increased along with the clinical state of the NSCLC. HSP90a has been shown to participate in the metastasis of lung cancer. HSP90A is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.